said its experimental cancer drug Bexxar won't be on the agenda at the next Food and Drug Administration advisory panel meeting in February, as originally expected.
The drug company said the FDA still has work to do and is not yet ready to discuss the drug. This is second time the FDA has refused to discuss Bexxar, a treatment for low-grade non-Hodgkin's lymphoma. The company hopes to have Bexxar up for discussion at the next panel meeting, tentatively scheduled for June.
Shares of Corixa were recently down 9.6% to $13.35 in Instinet premarket trading after closing at $14.77 Wednesday on the Nasdaq.